Chemistry:Gusacitinib
From HandWiki
Gusacitinib (ASN002) is an investigational drug which acts as a pan-Janus kinase inhibitor, binding with similar affinity at JAK1, JAK2, JAK3 and TYK2, and also inhibiting spleen tyrosine kinase (SYK).[1] It is taken orally and was developed for the treatment of eczema and dermatitis.[2][3][4]
See also
References
- ↑ "Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections". Journal of Medicinal Chemistry 65 (2): 893–921. January 2022. doi:10.1021/acs.jmedchem.0c01467. PMID 33539089.
- ↑ "The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study". The British Journal of Dermatology 181 (4): 733–742. October 2019. doi:10.1111/bjd.17932. PMID 30919407.
- ↑ "Topical and systemic JAK inhibitors in hand eczema - a narrative review". Expert Review of Clinical Immunology 19 (4): 365–373. April 2023. doi:10.1080/1744666X.2023.2174526. PMID 36708316.
- ↑ "Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study". Journal of the American Academy of Dermatology 89 (2): 235–242. August 2023. doi:10.1016/j.jaad.2023.04.027. PMID 37094653.
 |  |
